Altimmune
ALT
118 hedge funds and large institutions have $375M invested in Altimmune in 2021 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 48 increasing their positions, 30 reducing their positions, and 15 closing their positions.
247% more call options, than puts
Call options by funds: $27.5M | Put options by funds: $7.92M
67% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 15
60% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 30
39% more capital invested
Capital invested by funds: $269M → $375M (+$106M)
11.69% more ownership
Funds ownership: 70.98% → 82.66% (+12%)
8% more funds holding
Funds holding: 109 → 118 (+9)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$26.4M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$9.93M |
| 3 |
MWNA
Marshall Wace North America
New York
|
+$9.63M |
| 4 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
+$8.83M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
+$8.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$15.4M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$6.82M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$5.47M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$3.19M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.44M |
ALT Hedge Fund Activity: Q3 2021 in Review
118 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q3 2021, worth a combined $375M — up 39% from $269M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new ALT positions and 15 closed out — a net gain of 10 holders — while 48 added to existing stakes and 30 trimmed.
The largest buyer was Avidity Partners Management, opening a new position worth an estimated $26.4M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $15.4M sold.
- 118 institutional investors held Altimmune (ALT) as of Q3 2021, up from 109 in Q2 2021.
- Funds reported $375M of Altimmune stock for Q3 2021, up 39% quarter-over-quarter.
- 25 funds opened new Altimmune positions in Q3 2021 and 15 closed out, a net change of +10 holders.
- The largest Altimmune buyer in Q3 2021 was Avidity Partners Management, an estimated $26.4M added.
- The largest Altimmune seller in Q3 2021 was Point72 Asset Management, an estimated $15.4M sold.
Based on aggregated 13F filings for Q3 2021.